2269N Stock Chart & Stats
$66.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$66.00 - $66.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$361.21B
Enterprise Value$123.38K
Total Cash (Recent Filing)$15.74B
Total Debt (Recent Filing)$3.11B
Price to Earnings (P/E)28.4
Beta0.00
Next Earnings
Aug 26, 2026EPS Estimate
1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding4,143,562,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.53
Price to Sales (P/S)5.48
P/FCF Ratio42.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.82
Revenue Forecast (FY)$56.00B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross, EBIT and net margins indicate durable pricing power and operational efficiency in biologics services. Healthy margins support reinvestment into capacity and R&D, insulating returns even if top-line growth slows and enabling steady cash available for strategic programs.
Conservative Balance SheetVery low leverage provides financial flexibility to fund capex, absorb client timing shifts, and pursue capacity expansion without stress. A conservative balance sheet reduces refinancing risk and supports long-term investments critical to CRDMO competitiveness.
Integrated End-to-end CRDMO ModelOffering discovery through commercial manufacturing creates client stickiness and multi-phase revenue capture as programs mature. An integrated platform supports upsell, reduces client switching, and underpins a durable revenue base as biopharma outsources more complex biologics work.
Bears Say
Slowing Revenue GrowthA pronounced deceleration in top-line growth reduces visibility on future scale benefits and may delay transitions of client programs to higher-margin commercial manufacturing. Prolonged slower growth can limit margin leverage and constrain long-term earnings expansion.
Weak Cash Conversion & FCF VolatilityBelow-par cash conversion and historical negative FCF imply capex and working-capital sensitivity. Volatile free cash flow limits predictable internal funding for capacity or dividends and raises reliance on external financing for large expansions or M&A.
Margins Normalized Below Prior PeaksA retreat from 2021–22 peak margins suggests structural mix shifts, pricing pressure, or higher operating costs. If persistent, this normalization caps return on incremental revenue and increases the need for volume growth to drive absolute profit gains.
Wuxi Biologics (Cayman) News
2269N FAQ
What was Wuxi Biologics (Cayman)’s price range in the past 12 months?
Wuxi Biologics (Cayman) lowest stock price was $66.00 and its highest was $66.00 in the past 12 months.
What is Wuxi Biologics (Cayman)’s market cap?
Wuxi Biologics (Cayman)’s market cap is $361.21B.
When is Wuxi Biologics (Cayman)’s upcoming earnings report date?
Wuxi Biologics (Cayman)’s upcoming earnings report date is Aug 26, 2026 which is in 32 days.
How were Wuxi Biologics (Cayman)’s earnings last quarter?
Wuxi Biologics (Cayman) released its earnings results on Mar 24, 2026. The company reported $1.518 earnings per share for the quarter, missing the consensus estimate of $1.629 by -$0.111.
Is Wuxi Biologics (Cayman) overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman)’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) pay dividends?
Wuxi Biologics (Cayman) does not currently pay dividends.
What is Wuxi Biologics (Cayman)’s EPS estimate?
Wuxi Biologics (Cayman)’s EPS estimate is 1.16.
How many shares outstanding does Wuxi Biologics (Cayman) have?
Wuxi Biologics (Cayman) has 4,143,562,500 shares outstanding.
What happened to Wuxi Biologics (Cayman)’s price movement after its last earnings report?
Wuxi Biologics (Cayman) reported an EPS of $1.518 in its last earnings report, missing expectations of $1.629. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman)?
Currently, no hedge funds are holding shares in MX:2269N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.77%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman)
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.